-
公开(公告)号:US06376509B2
公开(公告)日:2002-04-23
申请号:US09867309
申请日:2001-05-29
申请人: Raman Kumar Bakshi , Ravi P. Nargund , Zhixiong Ye
发明人: Raman Kumar Bakshi , Ravi P. Nargund , Zhixiong Ye
IPC分类号: A61K3144
CPC分类号: C07D471/04 , C07K5/0202
摘要: Certain novel compounds and derivatives thereof are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
摘要翻译: 某些新化合物及其衍生物是人类黑皮质素受体的激动剂,特别是人黑皮质素-4受体(MC-4R)的选择性激动剂。 因此,它们可用于治疗,控制或预防对MC-4R的激活反应的疾病和病症,例如肥胖,糖尿病,性功能障碍,包括勃起功能障碍和女性性功能障碍。
-
2.NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS 有权
标题翻译: 新型吡咯烷衍生的BETA 3 ADRENERGIC RECEPTOR AGONISTS公开(公告)号:US20160235727A1
公开(公告)日:2016-08-18
申请号:US15026267
申请日:2014-09-29
申请人: Kenneth Jay Barr , Mark E. Scott , Christopher F. Thompson , Neville Anthony , Carolyn Michele Cammarano , Raman Kumar Bakshi , Subhendu Kumar Mohanty , Chandra Sekhar Korapala , Prashant R. Latthe , Vyjayanthi N. Kambam , Sujit Kumar Sarkar , Jayanth Thiruvellore Thatai
发明人: Kenneth Jay Barr , Mark E. Scott , Christopher F. Thompson , Neville Anthony , Carolyn Michele Cammarano , Raman Kumar Bakshi , Subhendu Kumar Mohanty , Chandra Sekhar Korapala , Prashant R. Latthe , Vyjayanthi N. Kambam , Sujit Kumar Sarkar , Jayanth Thiruvellore Thatai
IPC分类号: A61K31/4439 , C07C53/18 , C07D401/14 , C07D413/14 , A61K31/444 , A61K31/517 , A61K31/497 , A61K31/501 , C07D471/04 , C07D495/04 , A61K31/519 , C07D401/06 , C07C53/06
CPC分类号: A61K31/4439 , A61K31/437 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K45/06 , C07B2200/07 , C07C53/06 , C07C53/18 , C07D207/08 , C07D207/09 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04 , C07D495/04 , A61K2300/00
摘要: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of us ing the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
摘要翻译: 本发明提供式(I)化合物,其药物组合物及其用于治疗或预防由β3肾上腺素受体激活介导的疾病的方法。
-
公开(公告)号:US20150258074A1
公开(公告)日:2015-09-17
申请号:US14431485
申请日:2013-09-26
申请人: Kevin J. WILSON , David J. WITTER , Matthew H. DANIELS , Angie R. ANGELES , Phieng SILIPHAIVANH , David L. SLOMAN , Brendan O'BOYLE , Danielle FALCONE , Catherine WHITE , Ron FERGUSON , Wei ZHOU , Kathryn LIPFORD , Umar Faruk MANSOOR , Salem FEVRIRE , Xianhai HUANG , Ravi KURUKULASURIYA , Judson E. RICHARD , Shuyi TANG , Christopher BOYCE , Joseph KOZLOWSKI , Raman Kumar BAKSHI , Ganesh Babu UNAKARAN , Merck Sharp & Dohme Corp.
发明人: Kevin J. Wilson , David J. Witter , Matthew H. Daniels , Angie R. Angeles , Phieng Siliphaivanh , David Sloman , Brendan O'Boyle , Danielle Falcone , Catherine White , Ron Ferguson , Wei Zhou , Kathryn Lipford , Umar Faruk Mansoor , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Judson E. Richard , Shuyi Tang , Christopher Boyce , Joseph Kozlowski , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC分类号: A61K31/437 , A61K45/06 , A61K31/4545 , C07D471/04
CPC分类号: A61K31/437 , A61K31/4545 , A61K45/06 , C07D471/04
摘要: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
摘要翻译: 公开了具有吡唑并吡啶基结构的式(1.0)的ERK抑制剂及其药学上可接受的盐。 还公开了使用式(1.0)化合物治疗癌症的方法。
-
公开(公告)号:US09486448B2
公开(公告)日:2016-11-08
申请号:US15026267
申请日:2014-09-29
申请人: Kenneth Jay Barr , Mark E. Scott , Christopher F. Thompson , Neville Anthony , Carolyn Michele Cammarano , Raman Kumar Bakshi , Subhendu Kumar Mohanty , Chandra Sekhar Korapala , Prashant R. Latthe , Vyjayanthi N. Kambam , Sujit Kumar Sarkar , Jayanth Thiruvellore Thatai
发明人: Kenneth Jay Barr , Mark E. Scott , Christopher F. Thompson , Neville Anthony , Carolyn Michele Cammarano , Raman Kumar Bakshi , Subhendu Kumar Mohanty , Chandra Sekhar Korapala , Prashant R. Latthe , Vyjayanthi N. Kambam , Sujit Kumar Sarkar , Jayanth Thiruvellore Thatai
IPC分类号: C07C53/06 , C07C53/18 , C07D401/06 , C07D401/14 , C07D413/14 , C07D471/04 , A61K31/444 , A61K31/4439 , A61K31/497 , A61K31/501 , C07D495/04 , A61K31/519 , A61K31/517
CPC分类号: A61K31/4439 , A61K31/437 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K45/06 , C07B2200/07 , C07C53/06 , C07C53/18 , C07D207/08 , C07D207/09 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04 , C07D495/04 , A61K2300/00
摘要: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
摘要翻译: 本发明提供式(I)化合物,其药物组合物及其用于治疗或预防由β3肾上腺素受体激活介导的疾病的方法。
-
公开(公告)号:US20150266895A1
公开(公告)日:2015-09-24
申请号:US14431462
申请日:2013-09-26
申请人: Kevin J. WILSON , David J. WITTER , Phieng SILIPHAIVANH , Kathryn KIPFORD , David SLOMAN , Danielle FALCONE , Brendan O'BOYLE , Umar Faruk MANSOOR , Jongwon LIM , Joey L. METHOT , Christopher BOYCE , Lei CHEN , Matthew H. DANIELS , Salem FEVRIER , Xianhai HUANG , Ravi KURUKULASURIYA , Ling TONG , Wei ZHOU , Joseph KOZLOWSKI , Milana M. MALETIC , Bidhan A. SHINKRE , Jayanth Thiruvellore THATAI , Raman Kumar BAKSHI , Ganesh Babu KARUNAKARAN , MERCK SHARP & DOHME CORP.
发明人: Kevin J. Wilson , David J. Witter , Phieng Siliphaivanh , Kathryn Lipford , David Sloman , Danielle Falcone , Brendan O'Boyle , Umar Faruk Mansoor , Jongwon Lim , Joey L. Methot , Christopher Boyce , Lei Chen , Matthew H. Daniels , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Ling Tong , Wei Zhou , Joseph Kozlowski , Milana M. Maletic , Bidhan A. Shinkre , Jayanth Thiruvellore Thatai , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC分类号: C07D498/18 , A61K31/437 , A61K31/5377 , A61K31/496 , A61K45/06 , A61K31/4375 , C07D498/14 , A61K31/553 , C07D519/00 , C07D471/04 , C07D471/14
CPC分类号: C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00
摘要: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
摘要翻译: 公开了式(1)的ERK抑制剂及其药学上可接受的盐。 还公开了使用式(1)的化合物治疗癌症的方法。
-
6.
公开(公告)号:US07414057B2
公开(公告)日:2008-08-19
申请号:US10526178
申请日:2003-09-05
IPC分类号: C07D401/12 , C07D403/12 , A61K31/453 , A61K31/4545 , A61P3/04 , A61P3/10
CPC分类号: C07D401/12 , C07D211/18 , C07D211/22 , C07D211/62 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08
摘要: Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes.
摘要翻译: 某些新型哌嗪脲衍生物是人类黑皮质素-4受体(MC-4R)的激动剂,特别是MC-4R的受体亚型选择性激动剂。 它们可用于治疗,控制或预防对MC-4R活化反应的疾病和病症,例如肥胖症和糖尿病。
-
-
-
-
-